A fast-growing telehealth brand is moving deeper into weight care as demand for new drugs climbs.
Hims & Hers Health plans to add both oral and injectable versions of Novo Nordisk’s obesity and diabetes medicines later this month, expanding access for consumers nationwide.
The move arrives amid widespread interest in GLP-1 drugs, ongoing supply constraints, and rising out-of-pocket costs for patients.
Hims will start selling oral and injectable versions of Novo’s blockbuster obesity and diabetes medications later this month.
Why this expansion matters now
GLP-1 medicines have reshaped treatment for type 2 diabetes and chronic weight management.
Semaglutide, sold by Novo Nordisk as Ozempic and Wegovy, has shown significant weight loss and glucose control in clinical trials.
Oral semaglutide, sold as Rybelsus, offers a pill option for some patients who prefer not to use injections.
More than 40% of U.S. adults live with obesity, according to the CDC, and many struggle to access treatment.
Insurance coverage is uneven. Out-of-pocket prices can run over $1,000 per month for brand-name products.
What Hims could change for consumers
Hims built its business on telehealth visits, subscription delivery, and cash pricing that is easy to understand.
Offering oral and injectable GLP-1 options through a single platform could streamline evaluation, prescribing, and follow-up.
Doctors typically screen patients for BMI, medical history, and risk factors before prescribing these drugs.
Patients also need coaching on diet, activity, and side effect management.
- Potential benefits: simpler access, transparent pricing, home delivery.
- Key risks: limited supply, side effects, and unclear insurance coverage.
- Important questions: Are products branded or compounded? What clinical follow-up is included?
Supply, safety, and oversight
High demand has strained supplies for Ozempic and Wegovy since 2023, with intermittent shortages.
Some providers turned to compounding pharmacies when brand-name drugs were hard to find.
Federal regulators have warned against compounded versions that use semaglutide salts, which are different from the approved active ingredient.
Patients should confirm whether a product is an FDA-approved brand or a compounded alternative allowed during shortages.
GLP-1 drugs can cause nausea, vomiting, diarrhea, and, rarely, pancreatitis or gallbladder problems.
Doctors often start with lower doses and increase slowly to improve tolerability.
Industry impact and competitive pressure
Novo Nordisk and Eli Lilly dominate the market, with quarterly sales and market values rising over the past two years.
Consumer platforms such as Ro, WeightWatchers, and Amazon Clinic have expanded weight-care offerings to meet demand.
Hims entering the GLP-1 channel could intensify price competition, especially for telehealth visits and care bundles.
Pharmacies and payers are watching for signals on supply stability and formulary decisions.
What buyers should look for
Experts advise patients to verify the drug name, dose, and source before starting therapy.
They also recommend asking about monitoring, refill timing, and what happens during shortages.
- Confirm whether you will receive Ozempic, Wegovy, or Rybelsus, or a compounded product.
- Ask about total monthly cost, including visits, medication, and shipping.
- Review side effects and when to contact a clinician.
- Plan for long-term treatment, since stopping can lead to weight regain.
The entrance of a major telehealth retailer into GLP-1 prescribing underscores how weight care is changing.
If Hims secures reliable supply and keeps prices clear, more patients could access treatment without long waits.
But safety, oversight, and truthful labeling will remain the test.
Watch for details on sourcing, pricing, and insurance coordination as the rollout begins this month.
